Wall Street analysts have been reading the tea leaves before President Donald Trump's healthcare speech Friday, and some think pharmacy benefit managers (PBMs) could be in trouble. PBMs manage the lists of what drugs your healthcare provider will and will not pay for. They're supposed to keep costs down. But Trump officials have been saying that one of the main ways PBMs claim to do this, by taking rebates from drug manufacturers, actually creates incentives that drives prices up. Wall...


Become a member to take advantage of more features, like commenting and voting.

Jobs to Watch